EMA Approves First Nasal Adrenaline Spray for Anaphylaxis

The European Medicines Agency (EMA) has taken a significant step forward in allergy treatment by recommending approval for Eurneffy, the first nasal adrenaline spray for the emergency treatment of severe allergic reactions, known as anaphylaxis.

Anaphylaxis is a life-threatening condition that can occur rapidly after exposure to an allergen. It causes a range of symptoms, including difficulty breathing, a drop in blood pressure, and loss of consciousness. Current treatment involves adrenaline injections, which many people fear or are unable to administer correctly in an emergency.

How Does it Work?

Adrenaline, also known as epinephrine, is a hormone that constricts blood vessels, relaxes airways, and speeds up the heart. When administered nasally, Eurneffy is rapidly absorbed into the bloodstream, providing similar effects to an injection.

The safety and effectiveness of Eurneffy were evaluated in clinical trials involving hundreds of healthy adults. While direct comparisons to adrenaline injections in anaphylaxis patients were not feasible, the studies demonstrated that the nasal spray is well-tolerated and effectively delivers adrenaline to the body.

Overcoming Barriers to Treatment

The nasal spray format is expected to address several challenges associated with current treatment options. Many people with allergies avoid carrying adrenaline injectors due to fear of needles, difficulty using the device, or concerns about administering an injection in public. Eurneffy offers a potentially easier and less intimidating alternative.

Next Steps

The EMA’s recommendation is a positive development, but Eurneffy still requires final approval from the European Commission before it can be marketed in the EU. Once approved, individual countries will determine pricing and reimbursement.

With the potential to improve access to life-saving treatment for millions of allergy sufferers, Eurneffy represents a significant advance in the management of anaphylaxis.

For more detailed information, please visit: First nasal adrenaline spray for emergency treatment against allergic reactions